Praxis Precision Medicines Inc's Comment on Sales, Marketing and Customers
The patent families pertain to pharmaceutical formulations and methods of use involving ulixacaltamide and persistent sodium current blockers such as relutrigine and vormatrigine. These patents address treatments for disorders including essential tremor, Parkinson's disease, epilepsy (including pediatric epilepsy), migraine, pain, cephalgia, SUNCT, and SUNA. The patents are pending or granted in multiple jurisdictions, with expiration dates ranging from 2037 to 2045. Market segments covered include movement disorders, epilepsy, pediatric epilepsy, migraine, pain, and specific headache syndromes.
News about Praxis Precision Medicines Inc Contracts
In a significant stride towards innovative epilepsy management, Praxis Precision Medicines has unveiled promising topline results from its EMBOLD study, showcasing the disease-modifying potential of relutrigine for patients diagnosed with SCN2A and 8A developmental epilepsies. The study reported an impressive placebo-adjusted monthly motor seizure reduction of 46% during its double-blind period, igniting hope for families affected by these challenging conditions.Epilepsy, a neurological disorder that affects millions globally, often triggers debilitating seizures and poses substantial educational, emotional, and social challenges for patients and their loved ones. The promising findings from the EMBOLD study...
Praxis Precision Medicines to Participate in Upcoming April ConferencesBOSTON, April 05, 2024 - Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in the translation of genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, has recently announced its participation in several conferences scheduled for April.The company aims to leverage these conferences as an opportunity to showcase their latest advancements in the field of precision medicine for CNS disorders. With a commitment to translating genetic insights into effective therapies, Praxis Precision Medicin...
Praxis Precision Medicines, a leading biopharmaceutical company focused on developing precision therapies for central nervous system disorders, recently released an update on the progress of its clinical stage portfolio. In particular, the company reported positive preliminary analysis from the 15 mg cohort in the PRAX-628 study involving epilepsy patients with Photo-Paroxysmal Response (PPR), which has exceeded expectations. Praxis Precision Medicines expects to announce the topline results of the study in the first quarter of 2024, following the completion of the 45 mg cohort.Epilepsy with Photo-Paroxysmal Response (PPR) is a condition characterized by seizures triggered by exposure to certain visual stimu...
Praxis Precision Medicines Inc’s Comment on Sales, Marketing and Customers
The patent families pertain to pharmaceutical formulations and methods of use involving ulixacaltamide and persistent sodium current blockers such as relutrigine and vormatrigine. These patents address treatments for disorders including essential tremor, Parkinson's disease, epilepsy (including pediatric epilepsy), migraine, pain, cephalgia, SUNCT, and SUNA. The patents are pending or granted in multiple jurisdictions, with expiration dates ranging from 2037 to 2045. Market segments covered include movement disorders, epilepsy, pediatric epilepsy, migraine, pain, and specific headache syndromes.
Sources:
Praxis Precision Medicines Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Praxis Precision Medicines Inc’s corporate clients.
For your research, we’ve provided 9 tables on Praxis Precision Medicines Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
